Mid career · publishing since 2010
COVID-19 Clinical Research StudiesImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersLong-Term Effects of COVID-19CAR-T cell therapy research
Publications
89
Citations
3,123
Est. group size
~18
Recurring co-author estimate
Active years
16
Publishing since 2010
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 3,123p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 6.8p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~14 · 13% small-team papers (≤3 authors) · across 15 venues
Publication cadence
Publications per year over the last 10 years — averaging 6.8/year recently
Recent publications
- The Human Cardiac “Age‐OME”: Age‐Specific Changes in Myocardial Molecular Expression
Aging Cell · 2025
- Air pollution and Parkinson’s disease: A prospective cohort study with sex-stratified analysis in the UK biobank
NeuroToxicology · 2025
- The Molecular Landscape of the Ageing Human Heart
Heart Lung and Circulation · 2025
- Impact of race and ethnicity on clinical outcomes and recurrence post‐ureteral reconstruction
BJUI Compass · 2024
- Left ventricular myocardial molecular profile of human diabetic ischaemic cardiomyopathy
medRxiv · 2024
- Common FUE Graft Harvesting Problems and Solutions
International Society of Hair Restoration Surgery · 2023
- Supplemental Figure S5 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Supplemental Figure Legends from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Supplemental Methods from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Supplemental Figure S4 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Supplemental Figure S2 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Supplemental Figure S3 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Supplemental Figure S1 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Data from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
- Supplemental Figure S3 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
2023
Publishes in
- Circulation×7
- Journal of the American College of Cardiology×6
- Journal of the American Heart Association×3
- JAMA Internal Medicine×2
- American Journal of Kidney Diseases×2
Similar researchers
By research-topic overlap
- Tariq U. Azam
Medicine · University of Michigan
- Tonimarie Catalan
Medicine · University of Michigan
- Pennelope Blakely
Medicine · University of Michigan
- Husam Shadid
Medicine · University of Michigan
- Chelsea Meloche
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile